



Phone: 1-800-809-1265 Fax: 1-866-872-8920

MRN: _____

DOB: _____

STANDARD NEXVIAZYME™ (avalglucosidase alfa-ngpt) PLAN OF TREATMENT

NOTE: We may require MD office notes and may require a letter of Medical Necessity (depending on diagnosis), to be able to verify eligibility and payment for this treatment through patient's Medicare and/or other insurance plans.

1. Patient Name: _____ Height (inches): _____ Weight (lbs): _____

2. Allergies: _____

3. Diagnosis: E74.02: Pompe disease

Other ICD-10 Code: _____ Diagnosis description: _____

4. Pre-medications: Administered 30 minutes prior to infusion ***as selected:***

*** Premedication of an antihistamine, antipyretic and/ or corticosteroid is suggested prior to infusion**

<p>Acetaminophen:</p> <p><input type="checkbox"/> 650 mg PO</p> <p><input type="checkbox"/> 500 mg PO</p> <p><input type="checkbox"/> 325 mg PO</p> <p><input type="checkbox"/> 1000 mg PO</p>	<p>Diphenhydramine: <input type="checkbox"/> 25 mg IVP, <input type="checkbox"/> 50mg IVP, <input type="checkbox"/> 25 mg PO, <input type="checkbox"/> 50mg PO or</p> <p>Alternate oral antihistamine to diphenhydramine:</p> <p><input type="checkbox"/> Cetirizine 10 mg <input type="checkbox"/> Loratadine 10 mg <input type="checkbox"/> Fexofenadine <input type="checkbox"/> 60mgs or <input type="checkbox"/> 180mgs</p> <p>Methylprednisolone: <input type="checkbox"/> 125 mg IVP <input type="checkbox"/> 40 mg IVP or other _____ mg IVP</p> <p>Famotidine: <input type="checkbox"/> 20mg PO, <input type="checkbox"/> 40mg PO, <input type="checkbox"/> 20mg IVP, <input type="checkbox"/> 40mg IVP</p>
---	--

Pre-medicate with other: _____

CONFIDENTIAL Property of Palmetto Infusion / CONFIDENTIAL Property of Palmetto Infusion / CONFIDENTIAL Property of Palmetto Infusion

5. Orders:

NEXVIAZYME™ (avalglucosidase alfa-ngpt) IV as directed to infuse per protocol via pump with 0.22-micron filter, every two weeks. **Flush IV extension with 10ml D5W prior to infusion and flush IV tubing with 25mL D5W post infusion.**

6. Dosing:

- Patient weight of ≥ 30kg, the recommended dosing is 20mg/kg (of actual body weight) IV in 5% Dextrose every two weeks to be infused over 4 to 5 hours for initial and subsequent infusions.
- Patient weight of <30kg, the recommended dosing is 40mg/kg (of actual body weight) IV in 5% Dextrose every two weeks to be infused over approximately 7 hours for initial infusion and 5 hours for subsequent infusions.

Special orders: _____

If adverse drug reaction occurs, utilize the ADVERSE DRUG REACTION GUIDELINES

7. Physician's Signature: _____ / _____ Date: _____

No Stamp Signatures

(Dispense as written)

(Substitution permitted)

Printed Physician's Name with Credentials: _____ NPI: _____

8. Fax updated supporting clinical MD notes with each order renewal or change in orders

Infusion order forms and Adverse Drug Reaction Guidelines are available at www.palmettoinfusion.com



Phone: 1-800-809-1265 Fax: 1-866-872-8920

MRN: _____

DOB: _____

Guidelines for Prescribing NEXVIAZYME™ (avalglucosidase alfa-ngpt) (Required documentation with all initial referrals)

Patient Name: _____

Referral Date: _____

Include signed and completed **Plan of Treatment**. (MD must complete sections 1-8)
(Infusion order forms & Standard Adverse Reactions orders are available at www.palmettoinfusion.com under Agency/MD tab)

Include patient demographic information and insurance information. (Copy of insurance cards if available)

Supporting clinical MD notes to include any past tried and/or failed therapies, intolerance, outcomes, or contraindications to conventional therapy. Include any lab results and/or tests to support diagnosis.

- NEXVIAZYME™ is indicated for treatment for patients 1 year or older with late-onset Pompe disease (lysosomal acid alpha-glucosidase [GAA] deficiency)

Other as requested: _____

**** Warnings/Precautions:** ● **Hypersensitivity Reactions Including Anaphylaxis** Prior to NEXVIAZYME administration, consider pretreating with antihistamines, antipyretics, and/or corticosteroids. If a severe hypersensitivity reaction (e.g., anaphylaxis) occurs, NEXVIAZYME should be discontinued immediately, and appropriate medical treatment should be initiated. If a mild or moderate hypersensitivity reaction occurs, the infusion rate may be slowed or temporarily stopped. ● **Risk of Acute Cardiorespiratory Failure in Susceptible Patients:** Patients susceptible to fluid volume overload, or those with acute underlying respiratory illness or compromised cardiac or respiratory function for whom fluid restriction is indicated may be at risk of serious exacerbation of their cardiac or respiratory status during the NEXVIAZYME infusion. More frequent monitoring of vitals should be performed during NEXVIAZYME infusion in these patients. Some patients may require prolonged observation times. ● See full prescribing information.

Palmetto Infusion Services will complete insurance verification and submit all required clinical documentation to the patient's insurance company for eligibility. Our office will notify you if any further information is required. We will review financial responsibility with the patient and refer them to any available co-pay assistance as required. Thank you for the referral.

Please fax all information to 1-866-872-8920 or call 1-800-809-1265 for assistance.